Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma
Open accessAbstract
Background: 131 I‐Metaiodobenzylguanidine (131 I‐MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and 131 I‐MIBG is concentrated in the liver after 131 I‐MIBG therapy. The aim of our study was to analyze the effects of 131 I‐MIBG therapy on thyroid and liver function. Procedure: Pre‐ and post‐therapy thyroid and liver functions were reviewed in a total of 194 neuroblastoma patients treated with 131 I‐MIBG therapy. The cumulative incidence over time was estimated for both thyroid and liver toxicities. The relationship to cumulative dose/kg, number of treatments, time from treatment to follow‐up, sex, and patient age was examined. Results: In patients who presented with Grade 0 or 1 thyroid toxicity at baseline, 12 ± 4% experienced onset of or worsening to Grade 2 hypothyroidism and one patient developed Grade 2 hyperthyroidism by 2 years after 131 I‐MIBG therapy. At 2 years post‐131 I‐MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient asymptomatic transaminase elevation, frequently confounded by disease progression and other therapies. Conclusion: The prophylactic regimen of potassium iodide and potassium perchlorate with 131 I‐MIBG therapy resulted in a low rate of significant hypothyroidism. Liver abnormalities following 131 I‐MIBG therapy were primarily reversible and did not result in late toxicity. 131 I‐MIBG therapy is a promising treatment for children with relapsed neuroblastoma with a relatively low rate of symptomatic thyroid or hepatic dysfunction. Pediatr Blood Cancer 2011;56:191–201. © 2010 Wiley‐Liss, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Doses up to 30 Gy to the liver have resulted in less than 10% incidence of transient reversible hepatotoxicity.
“but doses up to 30 Gy to the liver have resulted in less than 10% incidence of transient reversible hepatoxicity ( 52 , 53 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [52]
The Discussion reports that fewer than 10% of evaluable patients had grade 3 or 4 liver toxicity possibly attributable to ¹³¹I-MIBG, and the Results say the abnormalities in those patients returned to normal. But the figure does not cover hepatotoxicity of any grade: the Discussion reports 76±4% with onset or worsening of liver toxicity of any grade. The Discussion cites a separate dosimetry study for the estimate of less than 30 Gy to the liver; it does not establish the incidence specifically among patients whose liver received doses up to 30 Gy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269 · see citing works
Breslow, N. E., Cox, D. R., & Oakes, D. (1985) · Biometrics · doi:10.2307/2530888 · Cited by 4,382 · see citing works
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · see citing works
Self-citationCumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis
Kim, H. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1210 · Cited by 511 · see citing works
Mechanisms behind the non-thyroidal illness syndrome: an update
Warner, M., & Beckett, G. J. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0412 · Cited by 433 · see citing works
Encouraging outcome in pediatric oncology patients admitted to the intensive care unit
Poele, E. M. T., Bolt, R. J., de Bont, E. S., Beijer, L., & Albers, M. J. I. J. (2007) · University of Debrecen Electronic Archive (University of Debrecen) · doi:10.1002/pbc · Cited by 385 · see citing works
Matthay, K. K., Yanik, G. A., Messina, J. A., Quach, A., Huberty, J. P., Cheng, S., Veatch, J., Goldsby, R. E., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 265 · see citing works
Self-citationNakajo, M., Shapiro, B., Copp, J., Kalff, V., Gross, M. D., Sisson, J. C., & Beierwaltes, W. H. (1983) · PubMed · Cited by 224 · see citing works
Matthay, K. K., DeSantes, K. B., Hasegawa, B. H., Huberty, J. P., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., WEINBERG, V. K., & Price, D. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222 · see citing works
Self-citationMatthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B. L., Twomey, E., Horn, B. N., Reynolds, C. P., Groshen, S. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 195 · see citing works
Self-citationThyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence
Acharya, S., Sarafoglou, K., LaQuaglia, M. P., Lindsley, S. K., Gerald, W. L., Wollner, N., TAN, C. T. C., & Sklar, C. A. (2003) · Cancer · doi:10.1002/cncr.11362 · Cited by 185 · see citing works
Osenga, K. L., Hank, J. A., Albertini, M. R., Gan, J., Sternberg, A. G., Eickhoff, J. C., Seeger, R. C., Matthay, K. K., Reynolds, C. P., Twist, C. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2000 · Cited by 178 · see citing works
Self-citationLashford, L. S., Lewis, I. J., Fielding, S. L., Flower, M. A., Meller, S., Kemshead, J. T., & Ackery, D. M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1889 · Cited by 162 · see citing works
Matthay, K. K., Panina, C., Huberty, J. P., Price, D. C., Glidden, D. V., Tang, H. R., Hawkins, R. A., Veatch, J., & Hasegawa, B. H. (2001) · PubMed · Cited by 161 · see citing works
Self-citationGaze, M. N., Chang, Y.-C., Flux, G., Mairs, R. J., Saran, F. H., & Meller, S. T. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.195 · Cited by 141 · see citing works
Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.124 · Cited by 137 · see citing works
Self-citationMatthay, K. K., Quach, A., Huberty, J. P., Franc, B. L., Hawkins, R. A., Jackson, H. A., Groshen, S. G., Shusterman, S., Yanik, G. A., Veatch, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7628 · Cited by 121 · see citing works
Self-citationDuBois, S. G., Messina, J. A., Maris, J. M., Huberty, J. P., Glidden, D. V., Veatch, J., Charron, M., Hawkins, R. A., & Matthay, K. K. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.058 · Cited by 117 · see citing works
Self-citationRadiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
DuBois, S. G., & Matthay, K. K. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.05.002 · Cited by 116 · see citing works
Self-citationGaraventa, A., Bellagamba, O., Piccolo, M. S. L., Milanaccio, C., Lanino, E., Bertolazzi, L., Villavecchia, G., Cabria, M., Scopinaro, G., Claudiani, F., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6694223 · Cited by 106 · see citing works
Klingebiel, T., Bader, P., Bares, R., Beck, J., Hero, B., Jürgens, H., Lang, P., NIETHAMMER, D., Rath, B., & Handgretinger, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00130-0 · Cited by 103 · see citing works
Garaventa, A., Gambini, C., Villavecchia, G., Cataldo, A. D., Bertolazzi, L., Pizzitola, M. R., Bernardi, B. D., & Haupt, R. (2003) · Cancer · doi:10.1002/cncr.11167 · Cited by 95 · see citing works
Weiss, B., Vora, A., Huberty, J. P., Hawkins, R. A., & Matthay, K. K. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200307000-00009 · Cited by 85 · see citing works
Self-citationvan Santen, H. M., de Kraker, J., van Eck‐Smit, B. L. F., de Vijlder, J. J. M., & Vulsma, T. (2002) · Cancer · doi:10.1002/cncr.10447 · Cited by 81 · see citing works
Mastrangelo, S., Tornesello, A., Diociaiuti, L., Pession, A., Prete, A., Rufini, V., Troncone, L., & Mastrangelo, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1645 · Cited by 80 · see citing works
131I-MIBG as a first-line treatment in high-risk neuroblastoma patients
Hoefnagel, C. A., deKraker, J., OLMOS, R. A. V., & te, P. A. V. (1994) · Nuclear Medicine Communications · doi:10.1097/00006231-199409000-00008 · Cited by 66 · see citing works
[131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma.
Hoefnagel, C. A., Voûte, P. A., de Kraker, J., & Olmos, R. A. V. (1991) · PubMed · Cited by 46 · see citing works
van Santen, H. M., de Kraker, J., van Eck‐Smit, B. L. F., de Vijlder, J. J. M., & Vulsma, T. (2003) · Cancer · doi:10.1002/cncr.11523 · Cited by 45 · see citing works
Picco, P. P., Garaventa, A., Claudiani, F., Gattorno, M., Bernardi, B. D., & Borrone, C. (1995) · Cancer · doi:10.1002/1097-0142(19951101)76:9 · Cited by 44 · see citing works
Endocrine late effects from multi-modality treatment of neuroblastoma
van Santen, H. M., de Kraker, J., & Vulsma, T. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.036 · Cited by 42 · see citing works
Lumbroso, J., Hartmann, O., & Schlumberger, M. J. (1992) · PubMed · Cited by 41 · see citing works
Voûte, P. A., Hoefnagel, C. A., de Kraker, J., Olmos, R. A. V., Bakker, D. J., & van der Kleij, A. J. (1991) · PubMed · Cited by 39 · see citing works
Transient sialoadenitis: A complication of 131I‐metaiodobenzylguanidine therapy
Modak, S. I., Pandit-Taskar, N. D., Kushner, B. H., Kramer, K., Smith-Jones, P. M., Larson, S. M., & Cheung, N. V. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21391 · Cited by 38 · see citing works
Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.
Hutchinson, R. J., Sisson, J. C., Miser, J., Zasadny, K. R., Normolle, D. P., Shulkin, B. L., Francis, I. R., Wieland, D. M., & Shapiro, B. (1991) · PubMed · Cited by 34 · see citing works
Brans, B., Monsieurs, M. A., Laureys, G., Kaufman, J.-M., Thierens, H., & Dierckx, R. A. J. O. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1261 · Cited by 30 · see citing works
Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients.
Klingebiel, T., Feine, U., Treuner, J., Reuland, P., Handgretinger, R., & Niethammer, D. (1991) · PubMed · Cited by 24 · see citing works
Thyroid cancer after external or internal ionizing irradiation.
Papadopoulou, F., & Efthimiou, E. (2010) · PubMed · Cited by 18 · see citing works
Koral, K. F., Huberty, J. P., Frame, B. C., Matthay, K. K., Maris, J. M., Regan, D. D., Normolle, D. P., & Yanik, G. A. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0873-3 · Cited by 16 · see citing works
Self-citationHoefnagel, C. A., Maes, R. A. A., Beijnen, J. H., & Wafelman, A. R. (1996) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0038-1629825 · Cited by 11 · see citing works
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- [27]Matthay KK Huberty K 131I-Metaiodobenzylguandine (131I-MIBG) Double Infusion with Autologous Stem Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma (NANT) Phase 1 Study J Clin Oncol 2008 QA in press PMC2738616 19171714
- [38]Jacobsson L Johansson L Lindberg S Fjalling M Biokinetics and dosimetry of 131-I-metaiodobenzylguanidine (MIBG) Proceeding of Fourth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, TN 1985 MS
Cited by
Sorted by citations
Targeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456 · see citing works
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 419 · see citing works
Self-citationOverview and recent advances in the treatment of neuroblastoma
Whittle, S. B., Smith, V. R., Doherty, E., Zhao, S., McCarty, S. M., & Zage, P. E. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285230 · Cited by 397 · see citing works
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259 · see citing works
Promising Therapeutic Targets in Neuroblastoma
Matthay, K. K., George, R. E., & Yu, A. L.-T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1939 · Cited by 188 · see citing works
Self-citationThyroid Dysfunction from Antineoplastic Agents
Hamnvik, O. R., Larsen, P. R., & Marqusee, E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr373 · Cited by 165 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors
Simon, T., Hero, B., Schulte, J. H., Deubzer, H. E., Hundsdoerfer, P., von Schweinitz, D., Fuchs, J., Schmidt, M. C., Prasad, V., Krug, B., et al. (2017) · Klinische Pädiatrie · doi:10.1055/s-0043-103086 · Cited by 104 · see citing works
Norepinephrine Transporter as a Target for Imaging and Therapy
Pandit-Taskar, N. D., & Modak, S. I. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186833 · Cited by 104 · see citing works
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works
Øra, I., & Eggert, A. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.07.002 · Cited by 92 · see citing works
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
Yonekura, Y., Mattsson, S., Flux, G., Bolch, W. E., Dauer, L. T., Fisher, D. R., Laßmann, M., Palm, S., Hosono, M., Doruff, M., et al. (2019) · Annals of the ICRP · doi:10.1177/0146645319838665 · Cited by 87 · see citing works
Current Consensus on I-131 MIBG Therapy
Kayano, D., & Kinuya, S. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-018-0523-z · Cited by 82 · see citing works
Current and Future Strategies for Relapsed Neuroblastoma
Morgenstern, D. A., Baruchel, S., & Irwin, M. S. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318299d637 · Cited by 79 · see citing works
More, S. S., Itsara, M., Yang, X., Geier, E. G., Tadano, M. K., Seo, Y., VanBrocklin, H. F., Weiss, W. A., Mueller, S., Haas-Kogan, D. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2949 · Cited by 69 · see citing works
Self-citationMatthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098624 · Cited by 67 · see citing works
Self-citationParisi, M. T., Khalatbari, H. K., Park, J. R., Shulkin, B. L., & Yanik, G. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.02.002 · Cited by 66 · see citing works
Self-citationClement, S. C., van Eck‐Smit, B. L. F., van Trotsenburg, A. S. P., Kremer, L. C. M., Tytgat, G. A. M., & van Santen, H. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24681 · Cited by 57 · see citing works
Anticancer Drug-induced Thyroid Dysfunction
Bhattacharya, S., Goyal, A., Kaur, P., Medanta, T. M., Singh, R. K., & Kalra, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.32 · Cited by 49 · see citing works
Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma
Polishchuk, A. L., Li, R., Hill‐Kayser, C. E., Little, A., Hawkins, R. A., Hamilton, J., Lau, M., Tran, H. C., Strahlendorf, C., Lemons, R. S., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.004 · Cited by 41 · see citing works
Self-citationTheranostics: Evolution of the Radiopharmaceutical Meta-Iodobenzylguanidine in Endocrine Tumors
Sisson, J. C., & Yanik, G. A. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.11.004 · Cited by 37 · see citing works
Self-citationVöö, S. A., Bucerius, J. A., & Mottaghy, F. M. (2011) · Methods · doi:10.1016/j.ymeth.2011.10.006 · Cited by 36 · see citing works
Clement, S. C., van Rijn, R. R., van Eck‐Smit, B. L. F., van Trotsenburg, A. S. P., Caron, H. N., Tytgat, G. A. M., & van Santen, H. M. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2967-4 · Cited by 35 · see citing works
Thyroid Sequelae of Pediatric Cancer Therapy
Waguespack, S. G. (2018) · Hormone Research in Paediatrics · doi:10.1159/000495040 · Cited by 31 · see citing works
Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors
Kinuya, S., Yoshinaga, K., Higuchi, T., Jinguji, M., Kurihara, H., & Kawamoto, H. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-0960-z · Cited by 29 · see citing works
Reitzel, L. R., Nguyen, N., Cao, Y., Vidrine, J. I., Daza, P., Mullen, P. D., Velasquez, M. M., Li, Y., Cinciripini, P. M., Cofta-Woerpel, L. M., et al. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr095 · Cited by 25 · see citing works
Trieu, M., DuBois, S. G., Pon, E., Nardo, L., Hawkins, R. A., Marachelian, A., Twist, C. J., Park, J. R., & Matthay, K. K. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25816 · Cited by 24 · see citing works
Self-citationReimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
Graves, S. A., Bageac, A., Crowley, J., & Merlino, D. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262752 · Cited by 23 · see citing works
Gebauer, L., Jensen, O., Neif, M., Brockmöller, J., & Dücker, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312816 · Cited by 21 · see citing works
Caring for survivors of childhood cancer: it takes a village
Song, A., & Fish, J. D. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000681 · Cited by 20 · see citing works
Cattoni, A., Molinari, S., Riva, B., Marco, S. D., Adavastro, M., Faraguna, M. C., Garella, V., Medici, F., Nicolosi, M. L., Pellegrinelli, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064146 · Cited by 16 · see citing works
Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells
Szlasa, W., Janicka, N., Sauer, N., Michel, O., Nowak, B., Saczko, J., & Kulbacka, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889950 · Cited by 15 · see citing works
Geurten, C., Geurten, M., Hoyoux, C., & Lebrethon, M.-C. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0273 · Cited by 14 · see citing works
Mínguez, P., Gustafsson, J., Flux, G., & Gleisner, K. S. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/6/2532 · Cited by 12 · see citing works
Simon, T., Thole-Kliesch, T. M., Castelli, S., Timmermann, B., Jazmati, D., Schwarz, R., Fuchs, J., Warmann, S. W., Hubertus, J., Schmidt, M. C., et al. (2025) · Klinische Pädiatrie · doi:10.1055/a-2556-4302 · Cited by 10 · see citing works
Adverse reactions to therapeutic radiopharmaceuticals
Silindir‐Gunay, M., & Ozolmez, N. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111527 · Cited by 6 · see citing works
Ikeda, H., Hayashi, Y., Takahashi, N., Watabe, T., Kanai, Y., Shinohara, A., Kato, H., Watabe, H., Shimosegawa, E., & Hatazawa, J. (2018) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2018.05.021 · Cited by 7 · see citing works
Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats
Koç, G., Kuşkonmaz, Ş. M., Demirel, K., Koca, G., Akbulut, A., Yumuşak, N., Şeneş, M., Kırtıl, G., Korkmaz, M., & Çulha, C. (2021) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001454 · Cited by 5 · see citing works
Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors
Clement, S. C., Tytgat, G. A. M., van Trotsenburg, A. S. P., Kremer, L. C. M., & van Santen, H. M. (2022) · Annals of Nuclear Medicine · doi:10.1007/s12149-022-01743-7 · Cited by 5 · see citing works
Thyroid Dysfunction from Treatments for Solid Organ Cancers
Kotwal, A., & McLeod, D. S. A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.006 · Cited by 5 · see citing works
Fiz, F., Piticchio, T., Bottoni, G., Sorrentino, S., Fragola, M., Livellara, V., Trimboli, P., & Piccardo, A. (2024) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.24.03552-0 · Cited by 4 · see citing works
Thyroid hormones, iodine and iodides, and antithyroid drugs
Gales, L., & Aronson, J. K. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00041-3 · Cited by 3 · see citing works
Effets secondaires endocriniens de la radiothérapie : diagnostic, prévention et traitements
Lugat, A., Drui, D., Baron, S., Thébaud, E., Supiot, S., Jouglar, E., & Dore, M. (2022) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2021.12.008 · Cited by 3 · see citing works
Neuroendocrine Tumors: Therapy with 131I-MIBG
Carrasquillo, J. A., & Chen, C. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_26-1 · Cited by 3 · see citing works
Neuroendocrine Tumors: Therapy with 131I-MIBG
Carrasquillo, J. A., & Chen, C. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-26236-9_26 · Cited by 2 · see citing works
de Lijster, B., de Kanter, C. T. M. M., de Keizer, B., Tytgat, G. A. M., Vulsma, T., Offringa, M., & van Santen, H. M. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-022-00529-1 · Cited by 2 · see citing works
Treatment with 131I-mIBG (Metaiodobenzylguanidine): Indications, Procedures, and Results
Castellani, M. R., Scarale, A. F., Lorenzoni, A., Maccauro, M., Guill, J. B., & Luksch, R. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_19 · Cited by 1 · see citing works
Adverse Events in Targeted Radionuclide Therapy
Guja, K. E., Wu, J. T.-Y., Agordzo, H. L., Kwofie, J., Samaan, D., Nadel, H. R., Grady, E. E., & Shah, J. C. (2025) · Radiographics · doi:10.1148/rg.240143 · Cited by 1 · see citing works
Vu, H. M. C., 萱野, 大., Wakabayashi, H., Kuroda, R., & Kinuya, S. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02151-3 · Cited by 1 · see citing works
Tuli, G., Calcaterra, V., Mase, R. D., Vigone, M. C., Gastaldi, R., Ferrigno, R., Improda, N., Klain, A., Licenziati, M. R., Pellino, V., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02851-1 · Cited by 1 · see citing works
Potter, N. S., Wang, Z., Bornowski, E. C., Swanson, S. D., Wolfe, J. P., McLean, A. M., & Kopelman, R. (2024) · Materials Advances · doi:10.1039/d3ma00812f · Cited by 1 · see citing works
Neuroendocrine Tumors: Therapy with 131I-MIBG
O’Brien, S. R., & Pryma, D. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_93 · Cited by 1 · see citing works
Radionuclide Therapies and Correlative Imaging
Parihar, A. S., & Mittra, E. (2023) · doi:10.1002/9781119603627.ch32 · Cited by 1 · see citing works
Endocrine Complications and Paraneoplastic Syndromes
Yeung, S. J., & Gagel, R. F. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm139 · Cited by 1 · see citing works
I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors
Araz, M., & ÇAYIR, D. Ö. (2017) · InTech eBooks · doi:10.5772/intechopen.68573
Late Effects in Children and Adolescents with Neuroblastoma
Berthold, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-49140-6_25
Plakhotnyaya, V. M., Demidova, T. Y., & Gritskevich, Е. Y. (2021) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2021-10-2-150-152
Neuroendocrine Tumors: Therapy with 131I-MIBG
O’Brien, S. R., & Pryma, D. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_93-1
Childhood Neoplasms and Impact on Hormones
Hoyos-Martínez, A., & Horne, V. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_3
Endocrine Complications and Paraneoplastic Syndromes
Yeung, S. J., & Gagel, R. F. (2022) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm139.pub2
- Authors
- Quach, A., Ji, L., Mishra, V., Sznewajs, A., Veatch, J., Huberty, J., Franc, B., Sposto, R., Groshen, S., Wei, D., Fitzgerald, P., Maris, J. M., Yanik, G., Hawkins, R. A., Villablanca, J. G., & Matthay, K. K.
- Affiliations
- University of California, San Francisco (US)
- Children's Hospital Los Angeles (US)
- University of Southern California (US)
- Children's Hospital of Philadelphia (US)
- University of Michigan (US)
- Corresponding author
- Matthay, Katherine K.
- ORCID
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2010-09-09
- Volume
- 56
- Issue
- 2
- Pages
- 191-201
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- PMC
- PMC3006009
- OpenAlex
- W2157600980
- Cited by
- 60
- References
- 40
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 11 · 2021: 5 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 3
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Pediatric Blood & Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- Alex's Lemonade Stand Foundation for Childhood Cancer (UL1 RR024131)
- Dougherty Foundation (UL1 RR024131)
- Frank A. Campini Foundation (UL1 RR024131)
- National Institutes of Health (RR024131, UCSF- CTSI UL1 RR024131)
- U.S. Public Health Service (P01 81403)
- University of California, San Francisco (UL1RR024131)
- National Cancer Institute (R21 CA97758, P01CA081403, R21CA097758)
- National Center for Research Resources (UL1RR024131, UCSF-CTSI UL1 RR-024131)
- Topics
- Health Sciences › Medicine › Neurology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- 131I-MIBG therapy, metaiodobenzylguanidine, neuroblastoma, thyroid toxicity, hypothyroidism, hyperthyroidism, hepatotoxicity, liver function, radioiodine therapy, potassium perchlorate, late radiation toxicity, childhood cancer
- MeSH terms
- Adolescent, Antineoplastic Agents, Child, Clinical Trials as Topic, Female, Humans, Iodine Radioisotopes, Liver, Liver Function Tests, Male, Neuroblastoma, Thyroid Gland, 3-Iodobenzylguanidine, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
